

From: [Gildner, Jean](#)
To: [Janice Castillo \(jcastillo@Portola.com\)](mailto:jcastillo@Portola.com)
Subject: BLA 125586 Response to request for Information
Date: Saturday, April 21, 2018 3:55:58 PM
Attachments: [image001.png](#)

Dear Janice,

From the list of 33 subjects who experienced a thromboembolic event (TEE), please create a table with (a) subject ID list with b) TEE based on the grouped terms used in the label 3) AE study day referenced to the ANDEXXA infusion, so FDA can analyze the reason for the discrepancy.

Please acknowledge receipt of this email.

Sincerely, Jean

Jean F. Gildner MSHS, MT (ASCP)

Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration

Tel: 240-402-8296

jean.gildner@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.